CervoMed Inc. (CRVO) Financial Statements (2026 and earlier)

Company Profile

Business Address 20 PARK PLAZA
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:20,90038,9227,79322,52337,31418,516
Cash and cash equivalent8,2358,9997,79310,11437,31418,516
Short-term investments12,62929,923 12,409  
Other undisclosed cash, cash equivalents, and short-term investments36     
Receivables 4272,254915   
Prepaid expense406443437   
Deferred costs321     
Other current assets2020670   
Other undisclosed current assets8061,256749112510261
Total current assets:22,87943,0829,96522,63537,82418,776
Noncurrent Assets
Operating lease, right-of-use asset      149
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization      149
Intangible asset, including goodwill, after accumulated amortization      8,639
Intangible asset, excluding goodwill, after accumulated amortization      8,639
Other noncurrent assets   8 1616
Total noncurrent assets:   8 168,953
TOTAL ASSETS:22,87943,0829,97322,63537,83927,730
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,6563,8792,5962,4172,9282,322
Accounts payable1,4541,5116621,128947546
Accrued liabilities3,2022,3681,9331,2901,9801,776
Other undisclosed current liabilities      113
Total current liabilities:4,6563,8792,5962,4172,9282,436
Noncurrent Liabilities
Long-term debt and lease obligation:      36
Liabilities, other than long-term debt      444
Deferred income tax liabilities      444
Operating lease, liability      36
Total noncurrent liabilities:      480
Total liabilities:4,6563,8792,5962,4172,9282,915
Equity
Equity, attributable to parent18,22339,2027,37720,21834,91124,814
Common stock996210264
Additional paid in capital115,906109,86961,812165,848164,815130,660
Accumulated other comprehensive income (loss)656 (35)  
Accumulated deficit(97,698)(70,731)(54,441)(145,597)(130,005)(105,909)
Total equity:18,22339,2027,37720,21834,91124,814
TOTAL LIABILITIES AND EQUITY:22,87943,0829,97322,63537,83927,730

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues4,0079,7387,145   
Gross profit:4,0079,7387,145   
Operating expenses(32,301)(27,965)(14,958)(15,972)(24,677)(15,975)
Operating loss:(28,295)(18,227)(7,813)(15,972)(24,677)(15,975)
Nonoperating income1,3291,9365,641   
Investment income, nonoperating1,3371,937219   
Other nonoperating income (expense)(8)(1)5,422   
Loss from continuing operations before equity method investments, income taxes:(26,966)(16,291)(2,172)(15,972)(24,677)(15,975)
Other undisclosed income from continuing operations before income taxes    381137114
Loss from continuing operations before income taxes:(26,966)(16,291)(2,172)(15,591)(24,540)(15,861)
Income tax benefit     4441,675
Loss from continuing operations:(26,966)(16,291)(2,172)(15,591)(24,096)(14,185)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(24,096)(14,185)
Net loss attributable to parent:(26,966)(16,291)(2,172)(15,591)(24,096)(14,185)
Other undisclosed net loss available to common stockholders, basic      (1,950)
Net loss available to common stockholders, diluted:(26,966)(16,291)(2,172)(15,591)(24,096)(16,136)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(26,966)(16,291)(2,172)(15,591)(24,096)(14,185)
Comprehensive loss:(26,966)(16,291)(2,172)(15,591)(24,096)(14,185)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(50)56 (35)  
Comprehensive loss, net of tax, attributable to parent:(27,017)(16,234)(2,172)(15,627)(24,096)(14,185)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: